|
|
Article: Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis.
- Article from:
- PR Newswire
- Article date:
- February 1, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOTHELL, Wash. and CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. , a leader in developing therapeutics using advanced drug delivery technologies, and Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company , announced today a collaboration to develop and commercialize Nastech's Parathyroid Hormone (PTH1-34) nasal spray for the treatment of osteoporosis. Clinical and non-clinical studies on PTH1-34 nasal spray are currently being completed in preparation for Phase III clinical development.
Under terms of the agreement, Nastech will grant P&G rights to the worldwide development and commercialization of ...